^
Association details:
Biomarker:RET mutation
Cancer:Thyroid Gland Carcinoma
Drug:AST-487 (RET inhibitor, FLT3 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells

Excerpt:
Treatment of the RET mutant cell lines TT, TPC-1, and MZ-CRC-1 with... combined treatment with AST487 and INK128 at low concentrations suppressed growth and induced apoptosis.
DOI:
10.1530/ERC-13-0085